Indoxyl25 mg

Indoxyl is a potent non-steroidal anti-inflammatory drug (NSAID) of the indole acetic acid class, used to relieve pain, swelling, and inflammation in a range of musculoskeletal and inflammatory conditions.

Established / FDA-approved uses

• Moderate to severe rheumatoid arthritis (including acute flares of chronic disease)
• Moderate to severe osteoarthritis
• Ankylosing spondylitis
• Acute gouty arthritis (short-term use until the attack subsides)
• Acute painful shoulder (bursitis and/or tendinitis)

Guideline-supported / commonly accepted use

• Primary dysmenorrhea (painful menstrual cramps) — widely used, though this is not a core labeled indication in all markets.

Specialized hospital-only use

An intravenous formulation of Indoxyl is used in neonatal intensive care to promote closure of a hemodynamically significant patent ductus arteriosus (PDA) in premature infants. This use requires strict weight- and age-based dosing under specialist supervision and is not relevant to outpatient/oral therapy.

Indoxyl is a symptomatic treatment — it reduces pain and inflammation but does not alter the underlying course of arthritic disease.

Each capsule/tablet contains Indomethacin as the active pharmaceutical ingredient, commonly available in strengths of 25 mg and 50 mg (immediate-release), and 75 mg (sustained/extended-release). A rectal suppository form (commonly 50 mg or 100 mg) is also available in some markets, including Bangladesh. Excipients vary by manufacturer and formulation.

Indoxyl is a nonselective, non-steroidal anti-inflammatory drug (NSAID) belonging to the indole acetic acid derivative group. It is one of the most potent NSAIDs in clinical use and has been used for decades to treat inflammatory arthritic conditions, acute gout, and acute periarticular pain.

Indoxyl is available as immediate-release capsules, sustained-release capsules, and, in some markets, rectal suppositories. Compared with many other NSAIDs, Indoxyl is associated with a distinctly higher rate of central nervous system side effects such as headache, dizziness, and confusion, which is an important factor in choosing therapy and in patient counseling.

Non-Steroidal Anti-Inflammatory Drug (NSAID) — Indole Acetic Acid Derivative. Indoxyl belongs to the same broad NSAID class as diclofenac and sulindac, sharing similar mechanisms and class-wide cardiovascular and gastrointestinal risks, though Indoxyl is notably more potent and CNS side effects are more prominent.

Indomethacin works by non-selectively inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, thereby blocking the conversion of arachidonic acid to prostaglandins and thromboxanes. Prostaglandins mediate pain, inflammation, fever, and also play protective roles in the gastric mucosa, renal blood flow, and platelet function.

By suppressing prostaglandin synthesis, Indomethacin produces analgesic, anti-inflammatory, and antipyretic effects. Its strong COX inhibition explains both its high anti-inflammatory potency and its comparatively higher risk of gastrointestinal and CNS adverse effects relative to many other NSAIDs.

Pharmacokinetics: Indomethacin is well absorbed orally, is highly protein bound (>90%), undergoes hepatic metabolism (O-demethylation, N-deacylation) with some enterohepatic recirculation, and is eliminated renally and biliary with an elimination half-life of approximately 2–11 hours.

Indoxyl capsules should be swallowed whole with a full glass of water, taken with food or milk to reduce gastrointestinal irritation. Sustained-release capsules must not be crushed, chewed, or opened. If a rectal suppository formulation is prescribed, it should be inserted as directed by the physician, typically after a bowel movement. Remain upright (sitting or standing) for 15–30 minutes after taking a dose where possible, to reduce esophageal irritation.

Indoxyl has several well-documented, clinically significant interactions:

• Aspirin and other NSAIDs: Concurrent use increases the risk of gastrointestinal bleeding and ulceration without improving efficacy; aspirin may also reduce plasma levels of Indoxyl. Avoid combining.
• Anticoagulants (e.g., warfarin) and antiplatelet agents: Increased risk of serious bleeding; requires close monitoring if co-administration is unavoidable.
• Corticosteroids: Additive risk of gastrointestinal ulceration and bleeding.
• SSRIs/SNRIs: Increased risk of gastrointestinal bleeding when combined with Indoxyl.
• Lithium: Indoxyl reduces renal clearance of lithium, which can raise lithium levels to toxic concentrations; monitor lithium levels closely.
• Methotrexate: Indoxyl can reduce renal clearance of methotrexate, increasing the risk of methotrexate toxicity, particularly at higher methotrexate doses.
• ACE inhibitors, ARBs, and diuretics: Indoxyl can blunt their antihypertensive/diuretic effect and, especially in combination with diuretics ("triple whammy" with an ACE inhibitor/ARB), increases the risk of acute kidney injury.
• Cyclosporine and other nephrotoxic drugs: Increased risk of nephrotoxicity.
• Digoxin: Indoxyl may increase serum digoxin concentrations; monitor levels.

Most common (particularly notable with Indoxyl compared to other NSAIDs):

• Central nervous system: headache (the most frequently reported side effect), dizziness, vertigo, drowsiness, and occasionally confusion or mood changes — CNS effects occur more often with Indoxyl than with many other NSAIDs.
• Gastrointestinal: nausea, dyspepsia, abdominal pain, diarrhea or constipation.

Less common but serious (see Precautions and Warnings for full detail):

• Gastrointestinal ulceration, bleeding, or perforation.
• Cardiovascular thrombotic events (heart attack, stroke).
• Fluid retention, edema, and elevated blood pressure.
• Renal impairment.
• Elevated liver enzymes, rarely serious hepatic injury.
• Tinnitus or hearing disturbances.
• Blood disorders (e.g., low platelet or white cell counts) — rare.
• Serious skin reactions (e.g., Stevens-Johnson syndrome) — rare.

Pregnancy: Indoxyl, like other NSAIDs, should be avoided starting at 20 weeks of pregnancy because of the risk of fetal renal dysfunction leading to low amniotic fluid (oligohydramnios), which can lead to fetal complications. Indoxyl is contraindicated from around 30 weeks of gestation (third trimester) onward because of the risk of premature closure of the fetal ductus arteriosus and other fetal/neonatal complications. Earlier in pregnancy, Indoxyl should be used only if clearly needed, at the lowest effective dose for the shortest time, and only after consulting a physician, as potential benefit must be weighed against potential risk to the fetus.

Lactation: Indoxyl passes into breast milk in small amounts. Because of case reports of seizures in a breastfed infant and the general caution recommended for NSAIDs during lactation, Indoxyl should be used during breastfeeding only if clearly needed and under medical supervision, with the infant monitored for any unusual signs.

Cardiovascular Risk

Indoxyl, like other NSAIDs, can increase the risk of serious cardiovascular thrombotic events, including heart attack and stroke, which can be fatal. This risk may occur early in treatment and increases with duration of use and in patients with existing cardiovascular disease or risk factors. Indoxyl is contraindicated for perioperative pain in the setting of CABG surgery (see Contraindications).

Gastrointestinal Risk

NSAIDs, including Indoxyl, can cause serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can occur at any time during use, with or without warning symptoms, and can be fatal. Elderly patients and those with a prior history of peptic ulcer disease or GI bleeding are at greater risk.

Renal Effects

Long-term use of Indoxyl can impair renal function, particularly in patients with pre-existing renal impairment, heart failure, liver dysfunction, or those taking diuretics or ACE inhibitors/ARBs, and in the elderly. Renal papillary necrosis has been reported with prolonged NSAID use. Indoxyl should be avoided in severe renal impairment.

Hepatic Effects

Elevations of liver enzymes can occur; Indoxyl should be discontinued if abnormal liver test results persist or worsen, or if clinical signs of liver disease develop. Avoid in severe hepatic impairment.

CNS Effects

Indoxyl has a notably higher rate of CNS effects (headache, dizziness, confusion) compared with many other NSAIDs; caution is advised when driving or operating machinery, especially at treatment initiation, and particularly in elderly patients.

Elderly Patients

Elderly patients are more susceptible to gastrointestinal, cardiovascular, renal, and CNS adverse effects of Indoxyl; use the lowest effective dose for the shortest duration and monitor closely.

General

Use the lowest effective dose of Indoxyl for the shortest duration consistent with individual treatment goals.

Symptoms of Indoxyl overdose may include lethargy, drowsiness, nausea, vomiting, and epigastric pain, and in more severe cases gastrointestinal bleeding, headache, confusion, hypertension, acute kidney injury, respiratory depression, or seizures.

If an overdose of Indoxyl is suspected, seek immediate medical attention or contact emergency services/poison control right away. Treatment is supportive and should be provided in a medical facility; do not attempt specific home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric Use

Safety and efficacy of oral Indoxyl have not been well established for routine outpatient pediatric use, and it is generally not recommended in children outside of specialist care. The intravenous formulation of Indoxyl is used in a highly specialized hospital setting to close a patent ductus arteriosus in premature infants, dosed by a neonatologist based on age and weight; this use is unrelated to general oral pain/inflammation therapy.

Elderly (Geriatric) Use

Elderly patients are at higher risk of gastrointestinal, cardiovascular, renal, and CNS side effects with Indoxyl. Use the lowest effective dose for the shortest duration and monitor closely for adverse effects.

Renal Impairment

Use with caution and reduced dose in mild-to-moderate renal impairment; avoid in severe renal impairment.

Hepatic Impairment

Use with caution in mild-to-moderate hepatic impairment; avoid in severe hepatic impairment.

Duration of Indoxyl therapy depends on the indication: acute conditions such as gout flares or acute painful shoulder are typically treated for a few days up to about 2 weeks, using the lowest effective dose. Chronic conditions such as rheumatoid arthritis, osteoarthritis, or ankylosing spondylitis may require longer-term use, but treatment should be reassessed periodically by a physician, using the shortest duration and lowest dose that controls symptoms, given increasing cardiovascular and gastrointestinal risk with prolonged use.

Indomethacin belongs to the Non-Steroidal Anti-Inflammatory Drug (NSAID) class, specifically the indole acetic acid derivative subgroup, which also includes drugs such as sulindac and etodolac.

Indomethacin nonselectively inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing synthesis of prostaglandins and thromboxane A2 from arachidonic acid. This suppresses inflammation, pain signaling, and fever, but also reduces protective prostaglandins in the gastric mucosa and kidneys, which underlies its gastrointestinal and renal risk profile.

C (prior to 30 weeks gestation); contraindicated at or after approximately 30 weeks gestation (Category D-like risk in the third trimester per current labeling)

Routine oral use of Indoxyl in children has not been well established for safety and efficacy, and it is generally avoided outside specialist supervision. A specialized intravenous formulation of Indoxyl is used in neonatal intensive care units to promote closure of a hemodynamically significant patent ductus arteriosus in premature infants, typically under 1750 g birth weight, dosed by a neonatologist in a defined short course based on postnatal age. This specialized use is distinct from general anti-inflammatory/analgesic therapy and must only be undertaken by qualified specialists in a hospital setting.